olivLaw · US equity research
Inhibikase Therapeutics, Inc. IKT
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Inhibikase Therapeutics develops IKT-001, an oral prodrug of imatinib, for pulmonary arterial hypertension, a rare and progressive disease affecting approximately 50,000 Americans. The company is now in the pivotal Phase 3 IMPROVE-PAH study, with regulatory approvals in 26 countries, making the study's progress the key milestone for the company.
At the close of 05 Nov 2026, Inhibikase Therapeutics, Inc. (IKT) stock was 1.44 USD (−7.99% on the day), with market capitalisation 200.9 m USD, beta 1.50, 52-week range 1.41–2.52 USD. Latest reported quarter (Q2 2026): revenue of 0 USD, net income of -19.6 m USD, diluted EPS -0.11 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 32.4
- weak (30–45)
- Bollinger (20, 2)
- 1.39 – 1.91
- in the lower half of the band · %B 0.09 · band width 31.7%
- SMA 50 / 200
- 2.00 / 1.93
- mixed trend
- MACD (12, 26, 9)
- -0.14 / -0.14
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −27.3% | −1.1% | −26.2 pp | — |
| 3 months | −40.2% | −0.5% | −39.8 pp | — |
| 6 months | −27.6% | +4.4% | −32.0 pp | — |
| Year to date | −29.8% | +12.3% | −42.1 pp | — |
| 1 year | −15.3% | +13.5% | −28.8 pp | +2.5% |
| 3 years | +39.8% | +76.4% | −36.6 pp | +19.2% |
| 5 years | −88.9% | +63.7% | −152.6 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Research & development | 4.2 m | 7.2 m | 10.5 m | 5.3 m | 7.6 m | 6.4 m | 10.8 m | 13.4 m |
| SG&A | 1.6 m | 5.7 m | 5.2 m | 5.9 m | 5.6 m | 6.8 m | 7.4 m | 7.7 m |
| Operating income | -5.8 m | -12.9 m | -14.6 m | -10.8 m | -12.8 m | -13.8 m | -17.8 m | -21.1 m |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -5.8 m | -12.1 m | -13.7 m | -9.9 m | -11.9 m | -12.7 m | -16.4 m | -19.6 m |
| Diluted EPS | -0.65 | -0.17 ≈ | -0.15 | -0.11 | -0.13 | -0.10 ≈ | -0.10 | -0.11 |
| Operating cash flow | -4.9 m ≈ | -5.3 m | -4.1 m | -5.6 m ≈ | -10.6 m ≈ | -7.5 m | -12.1 m | -12.4 m ≈ |
| Capex | 0 ≈ | 0 | 13.4 k | 0 ≈ | 0 ≈ | 0 | 0 | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 698.5 k | 3.1 m | 123.4 k | 260.5 k | 0 | unavailable |
| Revenue YoY | unavailable | +343.9% | −96.0% | +111.0% | −100.0% | unavailable |
| Net income | -2.8 m | -14.8 m | -18.1 m | -19.0 m | -27.5 m | -48.3 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -0.81 | -4.28 | -3.16 | -1.16 | -0.49 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -407.7% | -476.9% | -14,625.9% | -7,304.7% | unavailable | unavailable |
| Free cash flow | unavailable | -14.3 m | -17.6 m | -18.1 m | -19.1 m | -27.8 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 178.8 m USD
- Financial debt
- 0 USD
- Net debt
- -178.8 m USD
- Equity
- 172.9 m USD
- Total assets
- 181.2 m USD
- Debt / equity
- 0.00x
- Current ratio
- 21.70x
- ROE
- -36.0%
- ROA
- -34.5%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 698.5 k | 3.1 m | 123.4 k | 260.5 k | 0 | — | SEC (XBRL)· 27 Mar 2025verified |
| Research & development | 893.8 k | 11.4 m | 12.0 m | 13.6 m | 17.2 m | 29.8 m | SEC (XBRL)· 26 Mar 2026verified |
| SG&A | 2.6 m | 6.5 m | 6.2 m | 6.7 m | 11.4 m | 23.6 m | SEC (XBRL)· 26 Mar 2026verified |
| Operating income | -2.8 m | -14.8 m | -18.1 m | -20.1 m | -28.6 m | -52.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Interest expense | 29.4 k | 19.9 k | — | — | — | — | SEC (XBRL)· 31 Mar 2022verified |
| Pre-tax income | — | — | — | — | -27.5 k | -48.3 k | SEC (XBRL)· 26 Mar 2026verified |
| Income tax | — | — | — | — | 0 | 0 | SEC (XBRL)· 26 Mar 2026verified |
| Net income | -2.8 m | -14.8 m | -18.1 m | -19.0 m | -27.5 m | -48.3 m | SEC (XBRL)· 26 Mar 2026verified |
| Diluted EPS | — | -0.81 | -4.28 | -3.16 | -1.16 | -0.49 | SEC (XBRL)· 26 Mar 2026verified |
| Weighted average diluted shares | — | 18.2 m | 4.2 m | 6.0 m | 23.7 m | 98.3 m | SEC (XBRL)· 26 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 14.0 m | 40.8 m | 7.2 m | 9.2 m | 97.5 m | 178.8 m | SEC (XBRL)· 26 Mar 2026verified |
| Current assets | 14.8 m | 42.5 m | 24.4 m | 14.2 m | 98.5 m | 180.1 m | SEC (XBRL)· 26 Mar 2026verified |
| Property, plant & equipment, net | — | 0 | 236.5 k | 73.4 k | 47.1 k | 0 | SEC (XBRL)· 26 Mar 2026verified |
| Total assets | 14.8 m | 42.5 m | 24.9 m | 14.5 m | 98.6 m | 181.2 m | SEC (XBRL)· 26 Mar 2026verified |
| Accounts payable | 1.7 m | 1.1 m | 1.2 m | 646.8 k | 943.0 k | 1.2 m | SEC (XBRL)· 26 Mar 2026verified |
| Short-term debt | — | 0 | 145.8 k | 150.1 k | 110.5 k | 0 | SEC (XBRL)· 26 Mar 2026verified |
| Long-term debt | — | 248.9 k | — | 381.8 k | — | — | SEC (XBRL)· 27 Mar 2024verified |
| Current liabilities | 4.7 m | 4.1 m | 3.7 m | 3.4 m | 3.7 m | 8.3 m | SEC (XBRL)· 26 Mar 2026verified |
| Total liabilities | 5.0 m | 4.1 m | 3.9 m | 3.5 m | 3.7 m | 8.3 m | SEC (XBRL)· 26 Mar 2026verified |
| Equity | 9.8 m † | 38.4 m † | 21.0 m † | 11.0 m † | 94.9 m † | 172.9 m † | SEC (XBRL)· 26 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.1 m | -14.3 m | -17.4 m | -18.1 m | -19.1 m | -27.8 m | SEC (XBRL)· 26 Mar 2026verified |
| Capex | — | 0 | 243.3 k | 14.2 k | 0 | 13.4 k | SEC (XBRL)· 26 Mar 2026verified |
| Free cash flow | — | -14.3 m ≈ | -17.6 m ≈ | -18.1 m ≈ | -19.1 m ≈ | -27.8 m ≈ | SEC (XBRL)· 26 Mar 2026derived |
| Investing cash flow | — | 0 | -16.0 m | 11.7 m | -37.0 m | 2.1 m | SEC (XBRL)· 26 Mar 2026verified |
| Financing cash flow | 15.1 m | 41.1 m | -204.8 k | 8.4 m | 103.5 m | 108.5 m | SEC (XBRL)· 26 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 200.9 m USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 15.8x | 100 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -21.2% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Inhibikase Therapeutics, Inc. (IKT). Latest full fiscal year: 2024; data up to 2026-06-30.
Figures computed from the financial statements: revenue 0 USD in 2024; YoY growth -100.0%; ROE -52.0%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 15.8x
What contradicts it
- FCF yield: -21.2%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| KYMRKymera Therapeutics, Inc. | 10.9 bn | — | -27.3% | -341.8% | −16.7% | +89% / +517% |
| KRYSKrystal Biotech, Inc. | 8.9 bn | 40.8 | 17.5% | 47.9% | +33.9% | +38% / +188% |
| CGONCG Oncology, Inc. | 5.7 bn | — | -26.4% | -3,602.7% | +254.7% | +45% / unavailable |
| SRRKScholar Rock Holding Corporation | 5.5 bn | — | -167.8% | — | unavailable | +3% / +261% |
| ADPTAdaptive Biotechnologies Corporation | 4.3 bn | — | -37.1% | -23.7% | +54.8% | +36% / +513% |
| RXRXRecursion Pharmaceuticals, Inc. | 2.2 bn | — | -48.7% | -697.1% | +26.9% | −24% / −49% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.0 bn | — | — | -37.4% | +94.1% | +6% / +30% |
| MAZEMaze Therapeutics, Inc. | 1.8 bn | — | -37.3% | -5,343.6% | unavailable | −14% / unavailable |
| MGTXMeiraGTx Holdings plc | 817.3 m | 12.1 | 72.2% | 19.9% | +144.6% | +3% / +63% |
| SLDBSolid Biosciences Inc. | 689.8 m | — | -76.9% | — | −40.6% | +14% / +119% |
| DNAGinkgo Bioworks Holdings, Inc. | 634.6 m | — | -56.3% | -260.0% | −25.1% | +7% / −81% |
| CADLCandel Therapeutics, Inc. | 615.2 m | — | -81.8% | — | 0.0% | +69% / +794% |
| AUTLAutolus Therapeutics plc | 335.4 m | — | -133.0% | -238.7% | +644.9% | −11% / −71% |
| OCGNOcugen, Inc. | 277.0 m | — | — | -1,367.6% | +8.8% | −34% / +111% |
| SABSSab Biotherapeutics, Inc. | 267.5 m | — | -11.3% | — | −100.0% | −26% / −70% |
| PLXProtalix BioTherapeutics, Inc. | 202.2 m | 10.9 | 31.2% | 23.5% | −1.2% | +41% / +66% |
| PALIPalisade Bio, Inc. | 202.2 m | — | -51.4% | -6,388.2% | unavailable | −45% / −88% |
| ARTVArtiva Biotherapeutics, Inc. | 201.9 m | — | -36.6% | — | −100.0% | +10% / unavailable |
| IKTInhibikase Therapeutics, Inc. | 200.9 m | — | -52.0% | — | −100.0% | −15% / +40% |
1- and 3-year price returns: for IKT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Inhibikase Therapeutics develops IKT-001, an oral prodrug of imatinib, for pulmonary arterial hypertension, a rare and progressive disease affecting approximately 50,000 Americans 1. The company is now in the pivotal Phase 3 IMPROVE-PAH study, with regulatory approvals in 26 countries 3, making the study's progress the key milestone for the company.
SWOT
Strengths
- The company has a Phase 3 product with orphan designation, a long patent position and a drug backed by many years of clinical use 13.
- Recent equity financings and share sales brought significant funds that could support the study until topline data are read out 23.
- The improved gastrointestinal profile, supported by preclinical and Phase 1 data presented at a major conference, is an important point of differentiation 2.
Weaknesses
- The company has no approved products, generates no product revenue and has recorded net losses since inception 12.
- It has no manufacturing facilities of its own and no experience in marketing or selling drugs, which could require partnerships 1.
- Operating expenses have risen quickly and the number of shares and warrants outstanding has expanded significantly 23.
Opportunities
- If the IMPROVE-PAH study confirmed its benefits, IKT-001 could become one of the few oral disease-modifying therapies for PAH 13.
- Orphan designation and possible market exclusivity could make the product more attractive to commercial partners 3.
- The PAH market is growing steadily, and interest in antiproliferative pathways created by sotatercept could favor adoption of a new treatment 1.
Threats
- Recent setbacks for therapies in the same class could reduce confidence among investors and physicians in the company's approach 1.
- Sotatercept and other new therapies could become the standard of care, which could complicate the positioning of IKT-001 1.
- If studies are delayed or funding becomes harder to obtain, the company could be forced to reduce or postpone development programs 12.
Risks
- Dependence on one producthigh
The company depends heavily on the success of IKT-001 in PAH, and an unfavorable result could affect the entire business 1.
- Phase 3 study riskhigh
The IMPROVE-PAH study could be delayed or fail to meet its primary endpoints, and results from earlier phases do not guarantee final success 13.
- Funding requirementsmedium
The company could need additional funds before data readout, and financing terms could be less favorable 12.
- Shareholder dilutionmedium
The large number of shares and warrants outstanding could reduce the stake of existing shareholders in future value 23.
- Dependence on third partieslow
Manufacturing and supply of raw materials depend on external suppliers, and losing them could affect the studies 1.
Investment thesis
What would need to be true (bull case)
- If Phase 3 IMPROVE-PAH confirmed benefits over placebo, the company could become the first with an oral antiproliferative therapy that modifies disease in PAH 13.
- The improved gastrointestinal profile and orphan designation could differentiate IKT-001 from other options on the market 23.
- Recently obtained funds could cover the study until the Part B data readout, reducing the immediate funding risk 23.
What would break the thesis
- Without Phase 3 efficacy data, the company's value remains speculative, and a failed study could seriously weaken its outlook 1.
- Recurring net losses and dilution from new share issues could continue until approval, if it ever comes 12.
- The failure of inhaled seralutinib shows how difficult the field is, and competition from sotatercept could limit market space for IKT-001 1.
What to watch
- Number of countries with regulatory approval for IMPROVE-PAH and start of enrollment at new sitesQ3 2026
- Enrollment progress in Part A and the start of Part B of the IMPROVE-PAH study2027
- Research and development expenses and available cash relative to the stated runway through data readoutQ3 2026
- Exercise of Series A and B warrants, which could bring additional funds2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapies to modify the course of cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) 1. Its lead product, IKT-001, is an oral prodrug of imatinib whose activity on type III receptor tyrosine kinases could potentially slow pulmonary vascular remodeling 1. At its latest quarterly report the company had no approved products and generated no product revenue, relying on equity financings 12.
In January 2025 the company paused risvodetinib development to focus resources on IKT-001, and in May 2025 it granted ABLi Therapeutics an exclusive license to that compound with possible milestone and royalty payments 1. In February 2025 it acquired CorHepta Pharmaceuticals, a deal that also brought a one-time non-cash charge for acquired in-process research and development 1. Together these transactions expanded the pipeline while concentrating research on PAH 1.
The company owns no manufacturing facilities and relies on third-party contract development and manufacturing organizations for preclinical and clinical materials 1. It has no sales or marketing capabilities and could develop products itself or license them to partners later 1. Its US patent protection for IKT-001 runs until 2039, with possible extension 1.
Segments
IKT-001 in PAH
IKT-001 is the lead product, an oral prodrug of imatinib developed for PAH, an orphan indication 1. The Phase 3 IMPROVE-PAH study has a Part A of about 140 patients and a Part B of about 346 patients, with different primary endpoints 3. In July 2026 the FDA granted orphan drug designation, which could bring tax credits and up to seven years of market exclusivity if approved 3.
Research and development
Research and development expenses are a significant part of operating costs, and the company expects them to rise in the coming years as studies advance 12. In the quarter ended June 30, 2026, R&D expenses rose compared with the prior year as IMPROVE-PAH expanded 3. The Parkinson's program has been largely wound down, with spending far lower than in the prior year 1.
Market context
The global PAH market was estimated at about 8.3 billion dollars in 2025 and could grow at a compound annual rate of 3.3 percent through 2034 1. Current standard therapies are mainly vasodilators, while sotatercept, approved in 2024, generated 1.44 billion dollars of revenue in 2025 and renewed interest in antiproliferative pathways 1. If IKT-001 were approved, it could compete for share as one of the few disease-modifying therapies 1.
Investor and prescriber interest in therapies targeting PDGFR and c-Kit pathways has grown since sotatercept's success, while the inhaled seralutinib results missed statistical significance, suggesting route of administration may matter 1. Primary research with PAH prescribers points to a continuing high unmet need 1.
Trends
- Interest in antiproliferative pathwaystailwind
Sotatercept's success has renewed interest in therapies targeting antiproliferative pathways in PAH, and IKT-001 is positioned within this trend 1. If this interest holds, the product could attract greater attention from physicians and investors 1.
- Results of inhaled seralutinibmixed
The statistical miss of inhaled seralutinib in the PROSERA study suggests sustained systemic exposure to tyrosine kinase inhibitors may be needed for efficacy 1. This supports the company's thesis but also shows how difficult the field is 1.
- Orphan drug regulationtailwind
The orphan drug designation granted in July 2026 could bring tax credits, fee exemptions and market exclusivity if the product is approved 3. This framework generally favors companies developing treatments for rare diseases.
- Reliance on equity financingheadwind
The company has raised capital through share issuances and at-the-market sales, and its funding needs could grow if studies are delayed 12. Weaker capital markets could make long-term funding harder to secure 1.
Competitive position
The main competitor named in the sources is sotatercept, a product approved in 2024 that acts on transforming growth factor-beta ligands and is commercialized by Merck & Co 1. Inhaled seralutinib, a tyrosine kinase inhibitor, is another competitor in advanced clinical development 1. Standard therapies such as ERAs, PDE5 inhibitors and prostacyclins also compete for patients 1.
The company's claimed advantages are a better gastrointestinal profile than imatinib and oral dosing with consistent systemic exposure, in contrast with inhaled therapies 12. However, sotatercept already has clinical data and revenue, while IKT-001 is not yet approved, which could limit near-term comparison 1.
- Merck & CoMRK
Company that launched sotatercept, an approved PAH treatment, in 2024, with reported revenue in 2025 1.
- Seralutinib developer
Developer of an inhaled tyrosine kinase inhibitor in advanced clinical studies for PAH whose PROSERA Phase 3 study did not reach its primary statistical endpoint 1.
- Standard PAH therapies (ERAs, PDE5 inhibitors, prostacyclins)
Vasodilators used as standard of care and still the first-line treatment options for patients 1.
- Inhaled imatinib developers (IMPAHCT study)
Inhaled imatinib approach that did not show a statistically significant therapeutic effect at relatively low doses 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report20 Oct 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report08 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report26 Aug 2026Item 4.01 · Financial statements and exhibits
- Quarterly report11 Aug 2026
- Current report11 Aug 2026Results of operations · Financial statements and exhibits
- Current report29 Jul 2026Item 3.02 · Financial statements and exhibits
- Current report23 Jul 2026Regulation FD disclosure · Financial statements and exhibits
- Current report14 Jul 2026Other events · Financial statements and exhibits
- Current report29 Jun 2026Departure or appointment of officers · Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Quarterly report12 May 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Inhibikase Therapeutics, Inc. · 26 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Inhibikase Therapeutics, Inc. · 11 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Inhibikase Therapeutics, Inc. · 11 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.